Evidence map›Paper›PMID 37234735›Full record

ArticleClinical and translational radiation oncology2023

Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients' registration database, Proton-Net.

Hideya Yamazaki, Kei Shibuya, Takuya Kimoto, Motohisa Suzuki, Masao Murakami, Kazuki Terashima, Tomoaki Okimoto, Takashi Iizumi, Hideyuki Sakurai, Masaru Wakatsuki and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Hideya YamazakiDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kei ShibuyaGunma University Heavy Ion Medical Center, Maebashi, Japan.
Takuya KimotoDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Motohisa SuzukiDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Koriyama, Japan.
Masao MurakamiDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Koriyama, Japan.
Kazuki TerashimaDepartment of Radiology, Hyogo Ion Beam Medical Center, Hyogo, Japan.
Tomoaki OkimotoDepartment of Radiology, Hyogo Ion Beam Medical Center, Hyogo, Japan.
Takashi IizumiDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, Japan.
Hideyuki SakuraiDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, Japan.
Masaru WakatsukiQST Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Osamu SuzukiOsaka Heavy Ion Administration Company, Otemae, Chuo-ku, Osaka-city, Osaka, Japan.
Norio KatohDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.
Takeshi ArimuraMedipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan.
Takashi OginoMedipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan.
Masaru TakagiProton Therapy Center, Sapporo Teishinkai Hospital, Sapporo, Hokkaido, Japan.
Masayuki ArayaProton Therapy Center, Aizawa Hospital, Matsumoto, Nagano, Japan.
Takahiro WakiDepartment of Radiology, Tsuyama Chuo Hospital, Tsuyama, Okayama, Japan.
Sae MatsumotoProton Therapy Center, Fukui Prefectural Hospital, Fukui, Fukui, Japan.
Hiroyuki OginoDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Takumi FukumotoDepartment of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Masayuki OhtsukaDepartment of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: To examine the role of proton beam therapy (PBT) in the treatment of extrahepatic biliary tract cancer (EBC). Methods and materials: We analyzed the data accumulated in the Proton-Net database, which prospectively registered all individual patient data treated with PBT in all Japanese proton institutions from May 2016 to June 2019. The primary endpoint was overall survival (OS), and the secondary endpoints were local control (LC), progression-free survival (PFS), and toxicity. Results: Ninety-three patients with unresectable and/or recurrent EBC were treated with PBT using a median prescribed dose of 67.5 Gy (RBE) (range, 50-72.6 Gy) in 25 (22-30 fractions). With a median follow-up of 16.3 months, the median survival time was 20.1 months and the 2-year OS was 37.8%. Two-year PFS and LC rates were 20.6% and 66.5%, respectively. Poor liver function (Child-Pugh B, C), a narrower distance between the tumor and digestive tract (2 cm >), and a larger tumor diameter (2 cm <) were identified as poor prognostic factors for OS. PBT-related grade 3 ≤ acute and late adverse events occurred in 5.4% and 4.3% of patients, respectively, including one gastrointestinal late toxicity (duodenal ulcer). Conclusions: This is the largest prospectively accumulated series of PBT for EBC, and PBT showed favorable outcomes with acceptable toxicity profiles.

Indexed as

Extrahepatic bile duct cancerProton beam therapy

Identifiers

PMID37234735
PMCPMC10206422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.